Related Experiment Video

Updated: Jun 5, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

Synthesis and proapoptotic properties of new casein kinase II inhibitors

Mirosława Koronkiewicz1, Magda Zukowska, Zdzisław Chilmonczyk

  • 1National Medicines Institute, 30/34 Chełmska St., 00-750 Warszawa, Poland.

Acta Poloniae Pharmaceutica
|January 15, 2011
PubMed

Insights

New casein kinase II (CK2) inhibitors, including 4,5,6,7-tetraiodobenzimidazole (TIBI), show strong anticancer potential. These compounds effectively induce apoptosis and cytostatic effects in leukemia cells, highlighting their therapeutic promise.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Casein kinase II (CK2) is a highly pleiotropic protein kinase involved in numerous cellular functions, including signal transduction, proliferation, and cell survival.
  • Elevated CK2 levels are observed in various cancers, where it modulates key oncoproteins and tumor suppressor proteins.
  • CK2 inhibitors represent a promising therapeutic strategy for cancer treatment, potentially used alone or in combination with existing chemotherapeutics.

Purpose of the Study:

  • To evaluate the proapoptotic and cytostatic activities of novel CK2 inhibitors, specifically 4,5,6,7-tetraiodobenzimidazole (TIBI) and its derivatives.
  • To assess the efficacy of these compounds against cancer cell lines, focusing on their mechanism of action.

Main Methods:

  • Synthesis and characterization of novel benzimidazole derivatives as CK2 inhibitors.
  • In vitro evaluation of compound activity using the promyelocytic leukemia cell line (HL-60).
  • Assessment of apoptosis induction, cytostatic effects, mitochondrial membrane potential changes, and cell cycle progression.

Main Results:

  • The compound 4,5,6,7-tetraiodobenzimidazole (TIBI) demonstrated potent CK2 inhibition with an IC50 of 38 nM.
  • All tested compounds, including TIBI derivatives, induced significant apoptosis and cytostatic effects in HL-60 cells.
  • The observed proapoptotic effects were both concentration- and time-dependent, accompanied by alterations in mitochondrial membrane potential and cell cycle distribution.

Conclusions:

  • Novel benzimidazole derivatives, particularly TIBI, are potent CK2 inhibitors with significant anticancer properties.
  • These compounds effectively induce apoptosis and cytostatic effects in leukemia cells, suggesting their potential as anticancer agents.
  • Further investigation into these CK2 inhibitors could lead to the development of new therapeutic strategies for cancer treatment.

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α11:27

A Guide to Production, Crystallization, and Structure Determination of Human IKK1/α

Published on: November 2, 2018

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Caspases01:24

Caspases

Caspase, a family of cysteine proteases, serve as effectors in apoptosis. The ced3 gene in C.elegans was first identified to be involved in apoptosis. This gene encodes the ced-3 caspase that is similar to the interleukin-1-beta converting enzyme or ICE in mammals. In addition to apoptosis, caspases also function in the inflammatory response. Inflammatory caspases are essential in activating pro-inflammatory cytokines that recruit immune cells and block the replication of pathogens inside cells.
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...